13 UGA I-Corps Accelerator teams from the May 2018 cohort presented on their work in transitioning their innovations into the marketplace.
Innovation Gateway and Ximbio have entered into 10 license agreements for 38 monoclonal antibodies against the following: Gamma-Glutamylcysteine Synthetase, Avian Thymic Hormone, Equine Tumor Necrosis Factor (TNF), Manduca sexta MsAPN1 receptor to Cry1A(c)protein from Bacillus thuringiensis, Schistosoma mansoni Circulating Cathodic Antigen, Profilins 1, 4 and 5, Actin-related proteins 6 and 8, and O-linked N-acetylglucosamine (O-GlcNAc).
Innovation Gateway executed a license agreement for a peanut cultivar developed by William Branch, department of crop and soil sciences, as well as one license agreement for a peanut cultivar developed jointly by Peggy Ozias-Akins, department of horticulture, and Corley Holbrook, U.S. Department of Agriculture.
Innovation Gateway executed multiple testing and option agreements for various experimental ornamental plant selections developed by John Ruter, department of horticulture; for various cotton lines developed by Peng Chee, department of crop and soil sciences; and an ornamental peanut selection developed by Wayne Hanna, department of crop and soil sciences.
In the column he penned for James Magazineon the powerful partnership between the University of Georgia and the state of Georgia, UGA President Jere Morehead emphasized the role of university research in contributing to economic development and vitality.
An Innovation Gateway staff member hosted visitors from two of the leading ornamental plant nursery growers and marketers in the world to meet with UGA Athens-based ornamental plant breeder